Literature DB >> 2164159

The candidate Wilms' tumour gene is involved in genitourinary development.

K Pritchard-Jones1, S Fleming, D Davidson, W Bickmore, D Porteous, C Gosden, J Bard, A Buckler, J Pelletier, D Housman.   

Abstract

Wilms' tumour is an embryonic kidney tumour thought to arise through aberrant mesenchymal stem cell differentiation and to result from loss of function of a 'tumour suppressor' gene(s). Both sporadic and syndrome-associated Wilms' tumours are accompanied by an increased frequency of abnormalities of the urinary tract and genitalia. Deletional analysis of individuals with the WAGR syndrome (for, Wilms' tumour, aniridia, genitourinary abnormalities and mental retardation) showed that a Wilms' tumour gene lies at chromosomal position 11p13. This led to the isolation of a candidate Wilms' tumour gene, encoding a zinc-finger protein which is likely to be a transcription factor. To gain insight into the role of this candidate gene in normal development and tumorigenesis, we have now performed in situ messenger RNA hybridization on sections of human embryos and Wilms' tumours. The candidate Wilms' tumour gene is expressed specifically in the condensed mesenchyme, renal vesicle and glomerular epithelium of the developing kidney, in the related mesonephric glomeruli and in cells approximating these structures in tumours. The other main sites of expression are the genital ridge, fetal gonad and mesothelium. These data suggest that (1) this candidate is indeed a Wilms' tumour gene, (2) the associated genital abnormalities are pleiotropic effects of mutation in the Wilms' tumour gene itself, in support of recent genetic analysis, and (3) this gene has a specific role in kidney development and a wider role in mesenchymal-epithelial transitions.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164159     DOI: 10.1038/346194a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  169 in total

Review 1.  Frasier and Denys-Drash syndromes: different disorders or part of a spectrum?

Authors:  A Koziell; R Grundy
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Genetic dissection of cadherin function during nephrogenesis.

Authors:  Ulf Dahl; Anders Sjödin; Lionel Larue; Glenn L Radice; Stefan Cajander; Masatoshi Takeichi; Rolf Kemler; Henrik Semb
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

3.  TTY2: a multicopy Y-linked gene family.

Authors:  E Makrinou; M Fox; M Lovett; K Haworth; J M Cameron; K Taylor; Y H Edwards
Journal:  Genome Res       Date:  2001-06       Impact factor: 9.043

Review 4.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 5.  Genetic determination of nephrogenesis: the Pax/Eya/Six gene network.

Authors:  Stephan Brodbeck; Christoph Englert
Journal:  Pediatr Nephrol       Date:  2003-12-13       Impact factor: 3.714

6.  A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells.

Authors:  D A Haber; H T Timmers; J Pelletier; P A Sharp; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

7.  The molecular basis of nephrogenesis and congenital kidney disease.

Authors:  J Bard
Journal:  Arch Dis Child       Date:  1992-08       Impact factor: 3.791

Review 8.  renal tumors and tumor-like lesions in pediatric patients.

Authors:  J M Kissane; L P Dehner
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

Review 9.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  Mice lacking the 68-amino-acid, mammal-specific N-terminal extension of WT1 develop normally and are fertile.

Authors:  Colin G Miles; Joan Slight; Lee Spraggon; Maureen O'Sullivan; Charles Patek; Nicholas D Hastie
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.